Search

The Salamanca Statement and subsequent international calls to action around inclusive education aim to meet Education for All goals and foster inclusive communities for learners within mainstream education. However, there are diverse interpretations of what inclusion means in practice that vary across local, national and international contexts. In developing inclusive pedagogies with teachers at the forefront of providing support, the use of labels to categorise particular groups of learners according to perceived learning needs can further marginalise them, affecting their sense of belonging in school and their academic and social identities. We present case studies drawn from two doctoral studies conducted in contextually and culturally different settings to understand learners' experiences of marginalisation in education. The experiences of learners of English as an additional language transferring from primary to secondary school in England illustrate marginalised positioning assigned by teachers' perceptions. The ability to 'settle in' to school of street-connected children transitioning (back) into education in Kenya is influenced by their interactions with peers, teachers and the wider community on and after the street. Findings emphasise the need for understanding experiences through shared narratives and dialogue, starting with learners' experiences to develop pedagogies and foster inclusive communities within and beyond schools.

Introduction Recent recommendations suppose temporomandibular joint (TMJ) involvement in juvenile idiopathic arthritis (JIA) is a risk factor of poor outcomes and severe disease course. Objectives To compare the clinical characteristics of patients with juvenile idiopathic arthritis with and without TMJ involvement. Methods We analyzed the data of 753 patients with juvenile idiopathic arthritis aged 2–17 years, depending on TMJ arthritis (n  = 43; 5.7%) or no TMJ arthritis (n  = 710; 94.3%). Clinical, laboratory characteristics and treatment regimens were compared. Odds ratio (OR) analysis of sensitivity (Se) and specificity (Sp) was performed to obtained the predictors of TMJ involvement. Results Despite the similar age of onset, TMJ arthritis was associated with longer course of the disease, polyarticular JIA category, use of systemic corticosteroids and longer achievement of remission with similar rate of biologic administration. TMJ arthritis was associated with involvement of cervical spine, hip and shoulder arthritis. The main risk factors, associated with TMJ involvement in JIA were active joints > 8 (OR = 14.9 (5.8; 38.3), P  = 0.0000001), delayed remission > 7 years (OR = 3.1 (1.6; 5.8), P  = 0.0004), delayed hip involvement (OR = 4.6 (0.9; 22.6), P  = 0.041), hip osteoarthritis (OR = 4.0 (1.2; 13.0), P  = 0.014), and avascular necrosis of the hip. Cervical spine arthritis (OR = 10.3 (5.4; 19.8), P  = 0.000001), and corticosteroid treatment (OR = 2.3 (1.2; 4.4), P  = 0.0007) were associated with TMJ arthritis. Patients with TMJ arthritis required more biologics (OR-3.2 (1.6; 6.2), P  = 0.0006). Oligoarticular JIA category and uveitis were protective against TMJ involvement. Data are in the table. E10 Table 1. Parameters.  TMJ arthritis, yes.  TMJ arthritis, no.  P -value.  JIA duration, years  5.5 (2.7; 11.7)  4.2 (1.9; 7.4)  0.058  JIA category        Oligoarthritis  1 (2.3)  203 (28.6)  0.0006  Polyarthritis  25 (58.1)  240 (33.8)    Psoriatic arthritis  2 (4.7)  38 (5.4)    Enthesitis-related arthritis  9 (20.9)  177 (24.9)    Systemic arthritis  6 (14)  52 (7.3)    Active joints, n (%)  17(10; 42)  6,0 (3,0; 11,0)  0,000  Hip osteoarthritis  8/13 (61.5)  40/140 (28.6)  0.014  Delayed hip involvement  8/10 (80.0)  58/125 (46.4)  0.041  Oral corticosteroids, n (%)  17/42 (40.5)  135/710 (19.0)  0.0007  Corticosteroids pulse-therapy, n (%)  13/43 (30.2)  122/707 (17.3)  0.032  Time before biologic, years  3.9 (1.0; 9.7)  4.2(1.9; 7.6)  0.912  Time before remission  4.2 (1.7; 10.8)  3.1 (1.5; 6.3)  0.042  Parameters.  TMJ arthritis, yes.  TMJ arthritis, no.  P -value.  JIA duration, years  5.5 (2.7; 11.7)  4.2 (1.9; 7.4)  0.058  JIA category        Oligoarthritis  1 (2.3)  203 (28.6)  0.0006  Polyarthritis  25 (58.1)  240 (33.8)    Psoriatic arthritis  2 (4.7)  38 (5.4)    Enthesitis-related arthritis  9 (20.9)  177 (24.9)    Systemic arthritis  6 (14)  52 (7.3)    Active joints, n (%)  17(10; 42)  6,0 (3,0; 11,0)  0,000  Hip osteoarthritis  8/13 (61.5)  40/140 (28.6)  0.014  Delayed hip involvement  8/10 (80.0)  58/125 (46.4)  0.041  Oral corticosteroids, n (%)  17/42 (40.5)  135/710 (19.0)  0.0007  Corticosteroids pulse-therapy, n (%)  13/43 (30.2)  122/707 (17.3)  0.032  Time before biologic, years  3.9 (1.0; 9.7)  4.2(1.9; 7.6)  0.912  Time before remission  4.2 (1.7; 10.8)  3.1 (1.5; 6.3)  0.042  Open in new tab E10 Table 1. Parameters.  TMJ arthritis, yes.  TMJ arthritis, no.  P -value.  JIA duration, years  5.5 (2.7; 11.7)  4.2 (1.9; 7.4)  0.058  JIA category        Oligoarthritis  1 (2.3)  203 (28.6)  0.0006  Polyarthritis  25 (58.1)  240 (33.8)    Psoriatic arthritis  2 (4.7)  38 (5.4)    Enthesitis-related arthritis  9 (20.9)  177 (24.9)    Systemic arthritis  6 (14)  52 (7.3)    Active joints, n (%)  17(10; 42)  6,0 (3,0; 11,0)  0,000  Hip osteoarthritis  8/13 (61.5)  40/140 (28.6)  0.014  Delayed hip involvement  8/10 (80.0)  58/125 (46.4)  0.041  Oral corticosteroids, n (%)  17/42 (40.5)  135/710 (19.0)  0.0007  Corticosteroids pulse-therapy, n (%)  13/43 (30.2)  122/707 (17.3)  0.032  Time before biologic, years  3.9 (1.0; 9.7)  4.2(1.9; 7.6)  0.912  Time before remission  4.2 (1.7; 10.8)  3.1 (1.5; 6.3)  0.042  Parameters.  TMJ arthritis, yes.  TMJ arthritis, no.  P -value.  JIA duration, years  5.5 (2.7; 11.7)  4.2 (1.9; 7.4)  0.058  JIA category        Oligoarthritis  1 (2.3)  203 (28.6)  0.0006  Polyarthritis  25 (58.1)  240 (33.8)    Psoriatic arthritis  2 (4.7)  38 (5.4)    Enthesitis-related arthritis  9 (20.9)  177 (24.9)    Systemic arthritis  6 (14)  52 (7.3)    Active joints, n (%)  17(10; 42)  6,0 (3,0; 11,0)  0,000  Hip osteoarthritis  8/13 (61.5)  40/140 (28.6)  0.014  Delayed hip involvement  8/10 (80.0)  58/125 (46.4)  0.041  Oral corticosteroids, n (%)  17/42 (40.5)  135/710 (19.0)  0.0007  Corticosteroids pulse-therapy, n (%)  13/43 (30.2)  122/707 (17.3)  0.032  Time before biologic, years  3.9 (1.0; 9.7)  4.2(1.9; 7.6)  0.912  Time before remission  4.2 (1.7; 10.8)  3.1 (1.5; 6.3)  0.042  Open in new tab Conclusion TMJ involvement is marker of poor disease prognosis. Early initiation of biologics and avoidance of corticosteroids might improve the risk of TMJ involvement. Ethics Written consent was obtained according to the declaration of Helsinki. This retrospective study's protocol was approved by the local Ethical Committee of Saint Petersburg State Pediatric Medical University (protocol number 11/10 from 23.11.2020). [ABSTRACT FROM AUTHOR]

Background Juvenile systemic lupus erythematosus (JSLE) is a severe life-threatening disease. The place of rituximab in JSLE management is still undefined. The early biologic intervention might improve disease's outcomes. Aim of study To assess the advantages of early rituximab administration compared with late. Material and methods In the retrospective cohort study the information about 36 JSLE patients, whom rituximab biosimilar BCD020 was initiated were included. All patients were divided in two groups: early start of rituximab (less than six months from onset) and late start (more than one year). We compared initial disease characteristics at onset, on the baseline (BL)—start of rituximab and end of the study—(EOS) - 12 months, and treatment characteristics. Results The time gap between early and late rituximab administration was 19 months. There were no differences in disease profile at onset, except higher SLEDAI and MAS frequency in early rituximab group. Baseline differences were: lower C3, C4, higher SLEDAI and oral daily corticosteroids dosage. At the end of the study, patient whom rituximab was prescribed early had more impressive changes in SLEDAI, e.g. 100% of patients decreased SLEDAI, compared with 79% in late rituximab group. The detailed information about disease activity and treatment outcomes in both groups are in the table. There were no differences in adverse events between groups, except more impressive signs of corticosteroid toxicity in group of late rituximab administration. Conclusion Early administration of rituximab biosimilar made it possible to control the JSLE activity faster and reduce the dose of corticosteroids effectively. There were no differences in adverse events, except signs of corticosteroid toxicity in group of late rituximab initiation. This work was financially supported by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075–15-2022–301). Ethics The study was approved by the Ethical Committee of the Saint-Petersburg State Pediatric Medical University (Protocol No1/3 from 11/Jan/2021). There were no violations of patient's rights according to the Declaration of Helsinki. OA03 Table 1. Parameter.  Early start of rituximab (n = 16).  Late start of rituximab (n = 19).  P -value.  Time before rituximab, months  3 (2; 6)  22 (14; 36)  0.00001  SLEDAI, BL, points  22 (15; 26)  10 (6; 16)  0.003  SLEDAI, EOS, points  2 (0; 4)  2 (0; 6)  1.0  SLEDAI changes from BL, points  -18 (-13; -24)  -6 (-14 -14)  0.0006  Patients, improved SLEDAI, %  16 (100)  15 (79)  0.05  SLEDAI changes from BL, %  85 (81; 100)  64 (14; 100)  0.099  Daily corticosteroids, BL, mg/kg  1.0 (0.6; 0.1)  0.3 (0.2; 0.8)  0.027  Daily corticosteroids, EOS, mg/kg  0.1 (0.08; 0.16)  0.1 (0.06; 0.2)  0.842  Median daily corticosteroids change from BL, %  85 (60; 88)  68 (33; 90)  0.436  Improvement in SLEDAI from BL        SLEDAI30  16 (100)  14 (74)  0.027  SLEDAI50  16 (100)  13 (68)  0.014  SLEDAI70  15 (94)  9 (47)  0.004  SLEDAI 90  7 (44)  7 (37)  0.678  SLEDAI100  5 (31)  6 (32)  0.984  Parameter.  Early start of rituximab (n = 16).  Late start of rituximab (n = 19).  P -value.  Time before rituximab, months  3 (2; 6)  22 (14; 36)  0.00001  SLEDAI, BL, points  22 (15; 26)  10 (6; 16)  0.003  SLEDAI, EOS, points  2 (0; 4)  2 (0; 6)  1.0  SLEDAI changes from BL, points  -18 (-13; -24)  -6 (-14 -14)  0.0006  Patients, improved SLEDAI, %  16 (100)  15 (79)  0.05  SLEDAI changes from BL, %  85 (81; 100)  64 (14; 100)  0.099  Daily corticosteroids, BL, mg/kg  1.0 (0.6; 0.1)  0.3 (0.2; 0.8)  0.027  Daily corticosteroids, EOS, mg/kg  0.1 (0.08; 0.16)  0.1 (0.06; 0.2)  0.842  Median daily corticosteroids change from BL, %  85 (60; 88)  68 (33; 90)  0.436  Improvement in SLEDAI from BL        SLEDAI30  16 (100)  14 (74)  0.027  SLEDAI50  16 (100)  13 (68)  0.014  SLEDAI70  15 (94)  9 (47)  0.004  SLEDAI 90  7 (44)  7 (37)  0.678  SLEDAI100  5 (31)  6 (32)  0.984  Open in new tab OA03 Table 1. Parameter.  Early start of rituximab (n = 16).  Late start of rituximab (n = 19).  P -value.  Time before rituximab, months  3 (2; 6)  22 (14; 36)  0.00001  SLEDAI, BL, points  22 (15; 26)  10 (6; 16)  0.003  SLEDAI, EOS, points  2 (0; 4)  2 (0; 6)  1.0  SLEDAI changes from BL, points  -18 (-13; -24)  -6 (-14 -14)  0.0006  Patients, improved SLEDAI, %  16 (100)  15 (79)  0.05  SLEDAI changes from BL, %  85 (81; 100)  64 (14; 100)  0.099  Daily corticosteroids, BL, mg/kg  1.0 (0.6; 0.1)  0.3 (0.2; 0.8)  0.027  Daily corticosteroids, EOS, mg/kg  0.1 (0.08; 0.16)  0.1 (0.06; 0.2)  0.842  Median daily corticosteroids change from BL, %  85 (60; 88)  68 (33; 90)  0.436  Improvement in SLEDAI from BL        SLEDAI30  16 (100)  14 (74)  0.027  SLEDAI50  16 (100)  13 (68)  0.014  SLEDAI70  15 (94)  9 (47)  0.004  SLEDAI 90  7 (44)  7 (37)  0.678  SLEDAI100  5 (31)  6 (32)  0.984  Parameter.  Early start of rituximab (n = 16).  Late start of rituximab (n = 19).  P -value.  Time before rituximab, months  3 (2; 6)  22 (14; 36)  0.00001  SLEDAI, BL, points  22 (15; 26)  10 (6; 16)  0.003  SLEDAI, EOS, points  2 (0; 4)  2 (0; 6)  1.0  SLEDAI changes from BL, points  -18 (-13; -24)  -6 (-14 -14)  0.0006  Patients, improved SLEDAI, %  16 (100)  15 (79)  0.05  SLEDAI changes from BL, %  85 (81; 100)  64 (14; 100)  0.099  Daily corticosteroids, BL, mg/kg  1.0 (0.6; 0.1)  0.3 (0.2; 0.8)  0.027  Daily corticosteroids, EOS, mg/kg  0.1 (0.08; 0.16)  0.1 (0.06; 0.2)  0.842  Median daily corticosteroids change from BL, %  85 (60; 88)  68 (33; 90)  0.436  Improvement in SLEDAI from BL        SLEDAI30  16 (100)  14 (74)  0.027  SLEDAI50  16 (100)  13 (68)  0.014  SLEDAI70  15 (94)  9 (47)  0.004  SLEDAI 90  7 (44)  7 (37)  0.678  SLEDAI100  5 (31)  6 (32)  0.984  Open in new tab [ABSTRACT FROM AUTHOR]